These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25490180)

  • 1. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
    Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
    Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
    Holmberg LA; Maloney DG; Connelly-Smith L
    Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30
    Grover NS; Hucks G; Riches ML; Ivanova A; Moore DT; Shea TC; Seegars MB; Armistead PM; Kasow KA; Beaven AW; Dittus C; Coghill JM; Jamieson KJ; Vincent BG; Wood WA; Cheng C; Morrison JK; West J; Cavallo T; Dotti G; Serody JS; Savoldo B
    Lancet Haematol; 2024 May; 11(5):e358-e367. PubMed ID: 38555923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
    Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
    Krishnan AY; Palmer J; Nademanee AP; Chen R; Popplewell LL; Tsai NC; Sanchez JF; Simpson J; Spielberger R; Yamauchi D; Forman SJ
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):922-929. PubMed ID: 28267593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
    McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Stuver R; Mian A; Brown S; Devlin S; Caimi PF; Chinapen S; Dahi P; Dean R; Epstein-Peterson ZD; Hill B; Horwitz SM; Lahoud O; Lin R; Moskowitz AJ; Sauter C; Shah G; Winter A; Jagadeesh D; Scordo M
    Am J Hematol; 2024 Jun; 99(6):1180-1183. PubMed ID: 38526002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation.
    Eyre TA; Barrington SF; Okosun J; Abamba C; Pearce RM; Lee J; Carpenter B; Crawley CR; Bloor AJC; Gilleece M; Nicholson E; Shah N; Orchard K; Malladi R; Townsend WM
    Haematologica; 2023 Mar; 108(3):785-796. PubMed ID: 35586966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
    Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
    Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.
    Bachanova V; Shanley R; Malik F; Chauhan L; Lamba V; Weisdorf DJ; Burns LJ; Lamba JK
    Biol Blood Marrow Transplant; 2015 May; 21(5):944-8. PubMed ID: 25677220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
    Lazarus HM; Carreras J; Boudreau C; Loberiza FR; Armitage JO; Bolwell BJ; Freytes CO; Gale RP; Gibson J; Hale GA; Inwards DJ; LeMaistre CF; Maharaj D; Marks DI; Miller AM; Pavlovsky S; Schouten HC; van Besien K; Vose JM; Bitran JD; Khouri IF; McCarthy PL; Yu H; Rowlings P; Serna DS; Horowitz MM; Rizzo JD;
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1323-33. PubMed ID: 19041053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.
    van Besien K
    Curr Opin Oncol; 2011 Nov; 23(6):681-91. PubMed ID: 21946246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 Anti-CD25-BEAM-Conditioning for Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma.
    Zain J; Tsai NC; Palmer JM; Simpson JR; Adhikarla V; Bading J; Yazaki P; Smith EP; Dandapani S; Song JY; Karras NA; Herrera AF; Salhotra A; Nademanee A; Nakamura R; Smith DL; Yamauchi DM; Poku EK; Biglang-Awa VE; Thomas SH; Colcher D; Shively JE; Wu AM; Forman SJ; Wong JY
    Blood Adv; 2024 Jun; ():. PubMed ID: 38838232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients.
    Benedetti E; Traverso G; Pucci G; Morganti R; Bramanti E; Cavallo F; Capochiani E; De Maria M; Ricchiuto V; Stella MS; Galimberti S
    Front Oncol; 2024; 14():1369601. PubMed ID: 38803538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affluence and Private Health Insurance Influence Treatment and Survival in Non-Hodgkin's Lymphoma.
    Comber H; De Camargo Cancela M; Haase T; Johnson H; Sharp L; Pratschke J
    PLoS One; 2016; 11(12):e0168684. PubMed ID: 27992551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further interferometric studies with mica; new multiple-beam fringes and their application.
    Proc R Soc Lond A Math Phys Sci; 1946 Jul; 186(Ser A):261-71. PubMed ID: 20992453
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
    Martin N; Borchiellini D; Coso D; Gastaud L; Boscagli A; Saudes L; Re D; Gutnecht J; Garnier G; Petit E; Barriere J; Naman H; Rossignol B; Thyss A; Peyrade F
    Leuk Lymphoma; 2015; 56(8):2379-87. PubMed ID: 25563428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
    Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.